Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This is a perspective clinical study to assess the safety and efficacy of PD-1 inhibitors in
patients with LT. Eligible patients have recurrent or metastatic cancer after LT, are not
amenable to, or refractory after, locoregional therapy or to a curative treatment approach
(eg, surgery, or ablation) and have previously been treated with sorafenib or other targeted
therapy, either intolerant to this treatment or show radiographic progression after
treatment.
Biopsy is needed to exclude patients with positive allograft PD-L1 expression.